Ronald Borchardt

Cardioxyl Pharmaceuticals, Inc. discovers and develops therapies and technologies for the treatment of cardiovascular diseases. It offers nitroxyl therapeutics, including CXL-1020, a nitroxyl donor compound for the intravenous treatment of acute decompensated heart failure and nitroxyl donor compounds for unmet medical needs in other cardiovascular indications. The company was founded by Vincent J. Kalish and Douglas Cowart in 2005 and is headquartered in Chapel Hill, NC.

RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Tom C. Melzer, Jay W. Schmelter, Mark J. Mendel and Andrew B. Craig III. The firm is headquartered in St. Louis, Missouri.

Sphaera Pharma Pvt Ltd. discovers and develops pharmaceutical drugs. The firm’s services include services such as in radio-chemistry, c-GMP manufacture, GLP studies, clinical formulations, structural biology and clinical development. The company was founded in 2008 and is headquartered in Gurgaon, India.

The University of Kansas Medical Center is a campus of the University of Kansas located in Kansas City, KS. It offers educational programs and clinical training through its schools of Health Professions, Medicine, Nursing, and Graduate Studies. The center operates multiple campuses throughout the state and provides quality, responsive services to underserved rural and urban communities. The center also hosts digital collections and databases to serve the research needs of students, researchers, and clinicians. Additionally, it offers international educational experiences that promote a diverse perspective and contributes to the cultural and economic well-being of the university, the state, and the nation. The Human Research Protection Program ensures the welfare of human subjects in research.